FDA May Cut Its Losses In Amarin Off-Label Promotion Case
This article was originally published in The Tan Sheet
Executive Summary
Amarin and FDA explore settlement of Vascepa suit. The agency could allow Amarin to proceed with its statements and disclosures rather than risk a difficult appeal to the Second Circuit, the same court that handed FDA a loss in Caronia three years ago.